TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market FacilityGlobeNewsWire • 05/06/20
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis JournalGlobeNewsWire • 05/01/20
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MDGlobeNewsWire • 04/29/20
TG Therapeutics: 2020 Offers Investors A Cascade Of Clinical And Regulatory CatalystsSeeking Alpha • 04/15/20
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular LymphomaGlobeNewsWire • 03/05/20
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/03/20
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular LymphomaGlobeNewsWire • 01/16/20
Options Traders Expect Huge Moves in TG Therapeutics (TGTX) StockZacks Investment Research • 01/10/20
TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional InvestorGlobeNewsWire • 12/23/19
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/12/19
TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as GlobeNewsWire • 10/24/19